Literature DB >> 17509255

Photodynamic therapy for non-melanoma skin cancer.

Sari M Fien1, Allan R Oseroff.   

Abstract

Photodynamic therapy (PDT) involves the administration of a photosensitizing drug and its subsequent activation by light at wavelengths matching the absorption spectrum of the photosensitizer. Because the skin is readily accessible to light-based therapies, PDT with systemic and particularly with topical agents has become important in treating cutaneous disorders. Topical PDT is indicated for treating actinic keratosis, superficial or thin non-melanoma skin cancer, including some cases of nodular basal cell carcinoma, and some cutaneous lymphomas. Advantages of aminolevulinic acid/methyl aminolevulinate PDT include the possibility of simultaneous treatment of multiple tumors and large surface areas, good cosmesis, and minimal morbidity, such as bleeding, scarring, or infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17509255     DOI: 10.6004/jnccn.2007.0046

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  11 in total

1.  Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema.

Authors:  Patrycja Mikolajewska; Ryan F Donnelly; Martin J Garland; Desmond I J Morrow; Thakur Raghu Raj Singh; Vladimir Iani; Johan Moan; Asta Juzeniene
Journal:  Pharm Res       Date:  2010-07-31       Impact factor: 4.200

2.  Activated T cells exhibit increased uptake of silicon phthalocyanine Pc 4 and increased susceptibility to Pc 4-photodynamic therapy-mediated cell death.

Authors:  David C Soler; Jennifer Ohtola; Hideaki Sugiyama; Myriam E Rodriguez; Ling Han; Nancy L Oleinick; Minh Lam; Elma D Baron; Kevin D Cooper; Thomas S McCormick
Journal:  Photochem Photobiol Sci       Date:  2016-05-10       Impact factor: 3.982

3.  Photosensitizing effectiveness of a novel chlorin-based photosensitizer for photodynamic therapy in vitro and in vivo.

Authors:  Li-Jun Zhang; Jun Bian; Lei-Lei Bao; Hai-Fei Chen; Yi-Jia Yan; Li Wang; Zhi-Long Chen
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-27       Impact factor: 4.553

4.  Automatic interstitial photodynamic therapy planning via convex optimization.

Authors:  Abdul-Amir Yassine; William Kingsford; Yiwen Xu; Jeffrey Cassidy; Lothar Lilge; Vaughn Betz
Journal:  Biomed Opt Express       Date:  2018-01-30       Impact factor: 3.732

Review 5.  Tailoring Adjuvant Radiation Therapy by Intraoperative Imaging to Detect Residual Cancer.

Authors:  Melodi J Whitley; Ralph Weissleder; David G Kirsch
Journal:  Semin Radiat Oncol       Date:  2015-05-14       Impact factor: 5.934

6.  Desferrioxamine shows different potentials for enhancing 5-aminolaevulinic acid-based photodynamic therapy in several cutaneous cell lines.

Authors:  Jiabin Yang; Yumin Xia; Xiaoming Liu; Shan Jiang; Layuan Xiong
Journal:  Lasers Med Sci       Date:  2009-08-25       Impact factor: 3.161

7.  Enhanced systemic immune reactivity to a Basal cell carcinoma associated antigen following photodynamic therapy.

Authors:  Edith Kabingu; Allan R Oseroff; Gregory E Wilding; Sandra O Gollnick
Journal:  Clin Cancer Res       Date:  2009-06-23       Impact factor: 12.531

8.  Subcellular location and photodynamic therapeutic effect of chlorin e6 in the human tongue squamous cell cancer Tca8113 cell line.

Authors:  Wei Luo; Rong-Sen Liu; Jian-Guo Zhu; Ying-Chao Li; Hong-Chen Liu
Journal:  Oncol Lett       Date:  2014-11-20       Impact factor: 2.967

9.  Mammary and extramammary Paget's disease: a study of 14 cases and the associated therapeutic difficulties.

Authors:  Vanessa D Andretta Tanaka; Jose Antonio Sanches; Luis Torezan; Ane Beatriz Niwa; Cyro Festa Neto
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

10.  In vitro photodynamic therapy with chlorin e6 leads to apoptosis of human vascular smooth muscle cells.

Authors:  Magdalena Wawrzyńska; Wojciech Kałas; Dariusz Biały; Ewa Zioło; Jacek Arkowski; Walentyna Mazurek; Leon Strzadała
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-02       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.